# A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

> **NCT03594058** · PHASE2 · COMPLETED · sponsor: **Velicept Therapeutics, Inc.** · enrollment: 1413 (actual)

## Conditions studied

- Overactive Bladder

## Interventions

- **DRUG:** Solabegron modified release tablets, low dose
- **DRUG:** Solabegron modified release tablets, high dose
- **DRUG:** Matching Placebo

## Key facts

- **NCT ID:** NCT03594058
- **Lead sponsor:** Velicept Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-09
- **Primary completion:** 2019-04-29
- **Final completion:** 2019-05-02
- **Target enrollment:** 1413 (ACTUAL)
- **Last updated:** 2020-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03594058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03594058, "A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03594058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*